Analyze Diet
BMC veterinary research2023; 19(1); 225; doi: 10.1186/s12917-023-03787-x

Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block.

Abstract: Lidocaine is a local anesthetic that is sometimes administered in combination with epinephrine. The addition of epinephrine increases the time lidocaine remains at the site of administration, thus prolonging the duration of effect. Due to their potential to prevent the visual detection of lameness, the administration of local anesthetics is strictly regulated in performance and racehorses. Recent reports of positive regulatory findings for lidocaine in racehorses suggests a better understanding of the behavior of this drug is warranted. The objective of the current study was to describe serum and urine concentrations and the pharmacokinetics of lidocaine and its primary metabolites following administration in combination with epinephrine, as a palmar digital nerve block in horses. Twelve horses received a single administration of 1 mL of 2% lidocaine HCl (20 mg/horse) with epinephrine 1:100,000, over the palmar digital nerve. Blood samples were collected up to 30 h and urine samples up to 48 h post administration. Lidocaine and metabolite concentrations were determined by liquid chromatography- mass spectrometry and pharmacokinetic (non-compartmental and compartmental) analysis was performed. Results: Serum concentrations of lidocaine and 3-hydroxylidocaine were above the LOQ of the assay at 30 h post administration and monoethylglycinexylidide (MEGX) and glycinexylidide (GX) were below detectable levels by 24 and 48 h, respectively. In urine, lidocaine, MEGX and GX were all non-detectable by 48 h post administration while 3-hydroxylidocaine was above LOQ at 48 h post administration. The time of maximal concentration for lidocaine was 0.26 h (median) and the terminal half-life was 3.78 h (mean). The rate of absorption (Ka) was 1.92 1/h and the rate of elimination (Kel) was 2.21 1/h. Conclusions: Compared to previous reports, the terminal half-life and subsequent detection time observed following administration of lidocaine in combination with epinephrine is prolonged. This is likely due to a decrease in systemic uptake of lidocaine because of epinephrine induced vasoconstriction. Results of the current study suggest it is prudent to use an extended withdrawal time when administering local anesthetics in combination with epinephrine to performance horses.
Publication Date: 2023-10-30 PubMed ID: 37904169PubMed Central: PMC10614310DOI: 10.1186/s12917-023-03787-xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research examines how lidocaine, a local anesthetic used in combination with epinephrine, is absorbed, metabolized, and eliminated in horses following a palmar digital nerve block, with a primary focus on its serum and urine concentrations and pharmacokinetics. The researchers suggest that the prolonged detection time of lidocaine when combined with epinephrine is due to a decrease in systemic uptake caused by the vasoconstriction induced by epinephrine.

Experiment Overview

  • This study involved the administration of lidocaine in combination with epinephrine to twelve horses, with concentrations of lidocaine and its main metabolites measured in the animals’ serum and urine.
  • In the experiment, each horse received a single administration of 1 mL of 2% lidocaine HCl, equivalent to 20 mg per horse, combined with epinephrine at a concentration ratio of 1:100,000.
  • This was given over the palmar digital nerve, with blood samples collected up to 30 hours after administration, and urine samples collected up to 48 hours afterward.
  • The researchers used liquid chromatography-mass spectrometry to determine the concentrations of lidocaine and its metabolites, and performed a pharmacokinetic analysis.

Key Findings

  • In the serum, lidocaine and 3-hydroxylidocaine remained above the lowest level of quantitation (LOQ) of the assay even 30 hours after the administration.
  • Meanwhile, the levels of monoethylglycinexylidide (MEGX) and glycinexylidide (GX) dropped below the detection levels after 24 and 48 hours, respectively.
  • In the urine samples, lidocaine, MEGX, and GX were all undetectable after 48 hours post-administration, while 3-hydroxylidocaine remained above the LOQ even 48 hours after administration.
  • The time to reach the highest concentration for lidocaine was observed to be around 0.26 hours on average, and the average terminal half-life was 3.78 hours.
  • The absorption rate (Ka) stood at 1.92 per hour, while the elimination rate (Kel) was 2.21 per hour.

Insights and Conclusion

  • The pharmacokinetics of lidocaine differ when it’s used in combination with epinephrine, as compared to its use alone. This is primarily attributed to the vasoconstriction induced by epinephrine, which decreases the systemic uptake of lidocaine, resulting in a prolonged terminal half-life and detection time.
  • This research suggests that more careful consideration of withdrawal times is required when administering local anesthetics like lidocaine in combination with epinephrine in performance horses, given that detection times are longer than previously thought.

Cite This Article

APA
Knych HK, Katzman S, McKemie DS, Arthur RM, Blea J. (2023). Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block. BMC Vet Res, 19(1), 225. https://doi.org/10.1186/s12917-023-03787-x

Publication

ISSN: 1746-6148
NlmUniqueID: 101249759
Country: England
Language: English
Volume: 19
Issue: 1
Pages: 225
PII: 225

Researcher Affiliations

Knych, Heather K
  • K.L. Maddy Equine Analytical Chemistry Laboratory, (Pharmacology Section) School of Veterinary Medicine, University of California, Davis, 620 West Health Science Drive, Davis, CA, 95616, USA. hkknych@ucdavis.edu.
  • Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA. hkknych@ucdavis.edu.
Katzman, Scott
  • Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA.
McKemie, Daniel S
  • K.L. Maddy Equine Analytical Chemistry Laboratory, (Pharmacology Section) School of Veterinary Medicine, University of California, Davis, 620 West Health Science Drive, Davis, CA, 95616, USA.
Arthur, Rick M
  • School of Veterinary Medicine, University of California, Davis, CA, USA.
Blea, Jeff
  • School of Veterinary Medicine, University of California, Davis, CA, USA.

MeSH Terms

  • Horses
  • Animals
  • Anesthetics, Local / pharmacology
  • Lidocaine
  • Epinephrine
  • Nerve Block / veterinary

Conflict of Interest Statement

The authors declare no competing interests.

References

This article includes 14 references
  1. Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations.. Anesth Prog 2012;59(2):90–102.
    doi: 10.2344/0003-3006-59.2.90pmc: PMC3403589pubmed: 22822998google scholar: lookup
  2. Vickroy TW. Local anesthetics.. .
  3. Alvarez AV, Schumacher J, DeGraves FJ. Effect of the addition of epinephrine to a lidocaine solution on the efficacy and duration of palmar digital nerve blocks in horses with naturally occurring forefoot lameness.. Am J Vet Res 2018;79(10):1028–34.
    doi: 10.2460/ajvr.79.10.1028pubmed: 30256149google scholar: lookup
  4. Bernards CM, Kopacz DJ. Effect ofeEpinephrine on lidocaine clearance in vivo: a microdialysis study in humans.. Anesthesiology 1999;91(4):962.
  5. Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies.. J Am Acad Dermatol 1997;37(5 Pt 1):765–71.
    doi: 10.1016/S0190-9622(97)70115-4pubmed: 9366824google scholar: lookup
  6. Soma LR, You Y, Robinson MA, Boston RC. Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse.. J Vet Pharmacol Ther 2018;41(6):825–37.
    doi: 10.1111/jvp.12695pubmed: 30028024google scholar: lookup
  7. Harkins JD, Mundy GD, Woods WE. Lidocaine in the horse: its pharmacological effects and their relationship to analytical findings.. J Vet Pharmacol Ther 1998;21(6):462–76.
  8. Soma LR, Behrend E, Rudy J, Sweeney RW. Disposition and excretion of flunixin meglumine in horses.. Am J Vet Res 1988;49(11):1894–8.
    pubmed: 3247913
  9. Minuto J, Bedenice D, Ceresia M, Zaghloul I, Böhlke M, Mazan MR. Clinical effects and pharmacokinetics of nebulized lidocaine in healthy horses.. Front Vet Sci 2022;9:984108.
    doi: 10.3389/fvets.2022.984108pmc: PMC9521615pubmed: 36187809google scholar: lookup
  10. Moore PA, Hersh EV, Papas AS. Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate.. Anesth Prog 2008;55(2):40–8.
  11. Scott DB, Jebson PJ, Braid DP, Ortengren B, Frisch P. Factors affecting plasma levels of lignocaine and prilocaine.. Br J Anaesth 1972;44(10):1040–9.
    doi: 10.1093/bja/44.10.1040pubmed: 4639822google scholar: lookup
  12. Dickey EJ, McKenzie HC, Brown KA, de Solis CN. Serum concentrations of lidocaine and its metabolites after prolonged infusion in healthy horses.. Equine Vet J 2008;40(4):348–52.
    doi: 10.2746/042516408X284664pubmed: 18267881google scholar: lookup
  13. Ahlers SJGM, Välitalo PAJ, Peeters MYM. Morphine glucuronidation and elimination in intensive care patients: a comparison with healthy volunteers.. Anesth Analg 2015;121(5):1261–73.
    doi: 10.1213/ANE.0000000000000936pubmed: 26332855google scholar: lookup
  14. Thomson AH, Elliott HL, Kelman AW, Meredith PA, Whiting B. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.. J Pharmacokinet Biopharm 1987;15(2):101–15.
    doi: 10.1007/BF01062338pubmed: 3612496google scholar: lookup

Citations

This article has been cited 0 times.